Pharmaceutical Prices: The Impact of the Launch Strategy - An Analysis of German Data

Arbeitspapier

This paper reports the results from a statistical analysis of pharmaceutical price negotiations in Germany, where the pricing system was changed in 2011 in order to tie prices more to the benefits of the pharmaceuticals. A multiple linear regression of 187 pharmaceuticals which were assessed from 2011 to 2017 suggests that, despite the change, the manufacturers' launch strategy (freely chosen first year price) still has a major impact on pricing while the impact of the additional benefit remains comparably small. Moreover, the data suggest that the assessment of the Federal Joint Committee - while not yet existing at the point - best explains the manufacturer's launch strategy, indicating that manufacturers know more than they reveal.

Object Details

• Language: Englisch

References and Relationships

• Bibliographic citation: Series: CESifo Working Paper ; No. 7879

Classification and Topics

• Classification: Wirtschaft ; Health: General
• Subject: AMNOG ; early benefit ; assessment ; pharmaceuticals

Contributors, Places and Time

• Event: Geistige Schöpfung
• (who): Böhler, Yvonne-Beatrice ; Lamping, Christian ; Wichardt, Philipp C.
• Event: Veröffentlichung
• (who): Center for Economic Studies and ifo Institute (CESifo)
• (where): Munich
• (when): 2019

Further information

• Handle: http://hdl.handle.net/10419/207270
• Last update: 10.03.2025, 11:45 AM CET